Jeff Cislini Sells 765 RVMD Shares at $207.32 Each, Totaling $158,599

Jeff Cislini, Senior Vice President and General Counsel of Revolution Medicines, Inc. (ticker RVMD), sold 765 shares on September 30, 2026, at $207.32 per share, totaling $158,599, according to the SEC Form 4 filing.

Who is Jeff Cislini and What is His Real Role at Revolution Medicines, Inc.

Jeff Cislini serves as Senior Vice President (SVP) and General Counsel at Revolution Medicines, a publicly traded biopharmaceutical company. In his role as chief legal officer, he oversees regulatory affairs, research contracts, compliance matters, and advises the executive team on clinical development strategies.

The position of General Counsel provides direct access to confidential information regarding clinical trials, licensing agreements, financing negotiations, and governance decisions. This role places the insider at the heart of decisions that can impact the company's valuation, necessitating the obligation to disclose each transaction involving the company's equity.

Transaction Details: 765 Shares at $207.32 Each

The Form 4 filing indicates that 765 shares were sold at a per-share price of $207.32 on September 30, 2026. The total proceeds from the sale amount to $158,599. The filing specifies that the stated price corresponds to the per-share value, distinct from the total calculated by multiplying the number of shares by this price.

Why Insiders Sell Their Shares – Possible Reasons

Executives may choose to liquidate a portion of their shares to diversify their portfolio, reduce exposure to a single stock, or fund personal projects. Diversification helps mitigate the overall risk of a portfolio, especially when a significant portion of net worth is concentrated in company shares.

Tax considerations may also motivate a sale. For instance, realizing gains or losses can be planned to optimize income tax liability or capital gains, depending on the taxpayer's fiscal calendar.

Liquidity needs, such as financing real estate purchases, debt repayment, or significant expenses, often constitute another common reason. In these cases, selling shares provides an immediate source of funds without resorting to borrowing.

How Individual Investors Track Form 4 Filings

The SEC Form 4 is published on the EDGAR platform of the Securities and Exchange Commission. Investors can access filings for free by searching for the ticker RVMD or the insider's name on the official website (https://www.sec.gov/Archives/edgar/data/1969082/000196908226000011/0001969082-26-000011-index.htm).

Online tools, such as WhaleWisdom, OpenInsider, or brokerage services offering insider alerts, aggregate Form 4 data and present it in filterable lists by date, transaction type, or transaction size. These tools save time and help quickly identify significant sales or purchases.

It is important to note that the information contained in Form 4 filings is limited to the reported transaction and does not reveal underlying motives. Investors should cross-reference this data with other sources, such as quarterly reports, press releases, and sector analyses, to form a more comprehensive view of the context.